FOI_7529

Internal Reference Number: FOI_7529

Date Request Received: 07/11/2023 00:00:00

Date Request Replied To: 16/11/2023 00:00:00

This response was sent via: By Email

Request Summary: acute myeloid leukaemia (AML) & chronic lymphocytic leukaemia (CLL)

Request Category: Companies


Question Number 1: Patients with acute myeloid leukaemia (AML) 1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy? • Azacitidine monotherapy • Low dose cytarabine (LoDAC) monotherapy • Venetoclax + azacitidine • Venetoclax + LoDAC • Ivosidenib • Intensive chemotherapy-based regimen • Other

Answer To Question 1: Q1 - Azacytidine monotherapy <5 patient (originally on venetoclax/azacytidine) - Low dose cytarabine (LoDAC) monotherapy <5 - Venetoclax + Azacytidine 7 - Ivosidenib - <5 - Intensive chemotherapy based regimen <5 - Other <5

Question Number 2: 2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months? • Azacitidine monotherapy • Low dose cytarabine (LoDAC) monotherapy • Venetoclax + azacitidine • Venetoclax + LoDAC • Ivosidenib • Intensive chemotherapy-based regimen • Other Note: this should only include patients who have started first-line treatment during the 6-month window

Answer To Question 2: Q2 Azacitidine monotherapy <5 Low dose Cytarabine <5 Venetoclax + Azacitidine <5 Venetoclax and LoDAC - <5 Ivosidenib - <5 Intensive chemotherapy based regimen <5 Other <5

Question Number 3: 3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

Answer To Question 3: 8

Question Number 4: Patients with chronic lymphocytic leukaemia (CLL) 4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? Note: this should include patients who started treatment prior to the 6-month window

Answer To Question 4: 14

Question Number 5: 5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? Note: this should include only patients who have started treatment during the 6-month window

Answer To Question 5: 6

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.